Clindamycin Solution for Injection 150mg/ml (EU CTD Available: 2022)

Product description

Clindamycin 150mg/ml Solution for Injection (2ml & 4ml amps)  Dalacin® / PfizerDescription: Antibacterial.  Serious infections caused by susceptible Gram-positive organisms, staphylococci (both penicillinase- and non-penicillinase-producing), streptococci (except Streptococcus faecalis) and pneumococci. It is also indicated in serious infections caused by susceptible anaerobic pathogens such as Bacteroides spp, Fusobacterium spp, Propionibacterium spp, Peptostreptococcus spp. and microaerophilic streptococci.
Clindamycin does not penetrate the blood/brain barrier in therapeutically effective quantities.
Dossier Status: On-going / EU CTD Available: 2022
Stability Studies: Zone II / Zone IVb
Shelf life (Originator):   Two (2) years
Batch Sizes: To be defined
Pack Sizes: To be defined   
Originator pack: Box x 1, 5 & 10 Ampoules. 
Read more

Specifications

Categories Generic APIsGeneric Antibiotics; Finished Dosage FormsInjectables; Finished Dosage FormsOut-licensing
Sales markets Middle East Region (e.g. UAE); Oceania; North America (USA, Canada); Africa; Central America (e.g. Mexico); Europe - EU countries; Europe - non EU (e.g. UK, Russia, ex-CIS countries); South America (e.g. Brazil, Colombia); South East Asia (e.g. Thailand, Philippines, Singapore)
Supplied from Greece

More products from ANFARM HELLAS S.A.

View all our products (37)
Clindamycin Solution for Injection 150mg/ml (EU CTD Available: 2022)

Contact information

Address

Telephone

Website

View all contact information
CAPSULE CORE COMPETENCY

CAPSULE CORE COMPETENCY

Curia - From Curiosity to Cure

Curia - From Curiosity to Cure

Alfasigma  Contract Manufacturing Showroom

Alfasigma Contract Manufacturing Showroom

Wavelength Pharmaceuticals

Wavelength Pharmaceuticals

Datwyler Pharma Packaging

Datwyler Pharma Packaging